Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.54 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27943207 | 0.81 | IDO1 (0.46) | IDO1PNMTTAAR1ALDH1A1SIGMAR1 | |
| SCHEMBL3410728 | 0.80 | MCL1 (0.40) | IDO1ALDH1A1SMN1; SMN2TSHRNPC1 | |
| SCHEMBL12327284 | 0.80 | CYP3A4 (0.63) | IDO1PNMTTAAR1ALDH1A1SIGMAR1 | |
| SCHEMBL2172166 | 0.80 | PIK3CA (0.45) | IDO1PNMTTAAR1ALDH1A1TSHR | |
| SCHEMBL3397719 | 0.80 | IDO1 (0.34) | IDO1PNMTTAAR1ALDH1A1SIGMAR1 | |
| SCHEMBL2283019 | 0.80 | MEN1 (0.38) | IDO1PNMTTAAR1ALDH1A1L3MBTL1 | |
| SCHEMBL2173678 | 0.80 | MAPT (0.39) | IDO1PNMTTAAR1ALDH1A1SIGMAR1 | |
| SCHEMBL7044076 | 0.80 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2POLBKMT2A | |
| SCHEMBL3934805 | 0.80 | CA2 (0.58) | ALDH1A1TSHRIGF1RALOX15KMT2A | |
| SCHEMBL13725253 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRIGF1RALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429663-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024027795-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING MYC PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州开拓药业股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| WO-2023160582-A1 | THIAZOLAMINE MBL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022200162-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACECION PHARMA APS (DK) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | disclosed |
| EP-1084110-A1 | QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999055677-A1 | QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-04 | — | — | WO | disclosed |
| US-5053430-A | For treating schizophrenia | BOEHRINGER INGELHEIM KG (DE) | 1991-10-01 | — | — | US | disclosed |
| EP-0435988-A1 | 2-AMINO-7-CARBAMOYL-1,2,3,4-TETRAHYDRONAPHTHALENES, PROCESS FOR PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1991-07-10 | — | — | EP | disclosed |
| WO-1991001297-A1 | 2-AMINO-7-CARBAMOYL-1,2,3,4-TETRAHYDRONAPHTHALENES, PROCESS FOR PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1991-02-07 | — | — | WO | disclosed |
| EP-0361300-A1 | Use of 2,7 diamino-1,2,3,4-tetrahydronaphthalenes as drugs, 2,7 diamino-1,2,3,4-tetrahydronaphthalenes as well as processes for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1990-04-04 | — | — | EP | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| US-4560749-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | IDO1 2392/4885PNMT 3313/4885TAAR1 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.